Idiopathic Pulmonary Hemosiderosis as a Mimic of Pulmonary Vasculitis: A Case Report and Review of the Literature
AbstractPurpose of ReviewIdiopathic pulmonary hemosiderosis (IPH) is one of the rarest and least understood causes of pulmonary hemorrhage in children. Illustrated by a complex case presentation, we discuss the clinical manifestations, diagnosis, pathology, proposed etiologies, and treatment of this rare disease. We also compare IPH with anti-glomerular basement membrane antibody syndrome (anti-GBM disease), another rare causes of pediatric pulmonary hemorrhage.Recent FindingsRecent retrospective studies regarding IPH along with advanced immunotherapy have led to an improved understanding of how to best treat this condition, potential associations, and improved prognosis. Pathogenesis remains unknown, but several reports have suggested involvement of the alveolar capillary basement membrane.SummaryIPH is a poorly understood disease of unknown etiology that is a diagnosis of exclusion. Our patient was diagnosed with IPH after an exhaustive workup, including lung biopsy, into other immune-mediated causes of disease. While the pathogenesis of this rare disease remains elusive, our patient ’s immunofluorescent staining along the alveolar basement membrane without evidence of circulating antibody to type IV collagen raises the question of an immune-mediated pathogenesis of the disease with involvement of the alveolar basement membrane.
Authors: Bertamini L, Bonello F, Boccadoro M, Bringhen S Abstract INTRODUCTION: . The last twenty years have introduced new therapeutic agents for multiple myeloma (MM); these include proteasome Inhibitors (PIs), immunomodulatory drugs (IMDs) and monoclonal antibodies (mAbs). However, MM remains incurable, hence there is an unmet need for new agents for the treatment of advanced refractory disease. New agents could also be used in early lines to achieve improved, more sustained remission. AREAS COVERED: . We review the most promising agents investigated in early-phase trials for the treatment of MM and provide ...
Authors: Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, Marseglia GL, Miraglia Del Giudice M, Musarra A, Nettis E, Neri I, Patruno C, Stingeni L, Peris K, RADAR Group Abstract Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psycholog...
Condition: Asthma Interventions: Drug: Dupilumab SAR231893; Drug: Placebo Sponsor: Sanofi Not yet recruiting
Conditions: Allergy;Food; Adherence, Treatment; Child, Only Interventions: Behavioral: Food Allergy Superheroes Training (FAST) Program; Other: Food Allergy Knowledge Intervention Sponsors: Kent State University; Rhode Island Hospital; University of Memphis Recruiting
Conditions: Mesotheliomas Pleural; Malignant Pleural Mesothelioma Interventions: Device: intrapleural photodynamic therapy with videothoracoscopy; Drug: Nivolumab Injection Sponsors: University Hospital, Lille; Bristol-Myers Squibb Not yet recruiting
Conclusions The risk for cardiovascular disease in people with severe high-level spinal cord injury is a major clinical concern. Forthcoming studies in the SPICA will provide new knowledge of cardiopulmonary health in this cohort, which can guide future research and be used to develop long-term management.
Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia) is the first oral immunotherapy for children ages four to 17 years who have been diagnosed with a peanut allergy.Like subcutaneous forms of immunotherapy, Palforzia introduces the allergen in increasing doses and risks inducing allergic responses, including anaphylaxis.
Publication date: Available online 22 May 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Daniel A. Searing, Cullen M. Dutmer, David M. Fleischer, Marcus S. Shaker, John Oppenheimer, Mitchell H. Grayson, David Stukus, Nicholas Hartog, Elena W.Y. Hsieh, Nicholas L. Rider, Timothy K. Vander Leek, Harold Kim, Edmond S. Chan, Doug Mack, Anne K. Ellis, Elissa M. Abrams, Priya Bansal, David M. Lang, Jay Lieberman, David BK. Golden
Hydroxychloroquine has been touted as a potential treatment for COVID-19, but new observational data show it is not only without benefit but it increases death and arrhythmias.Medscape Medical News